Early clinical exploration has also shown encouraging results, including the combination of the HDAC inhibitor vorinostat with the immune checkpoint inhibitor pembrolizumab in recurrent cervical and other squamous carcinomas, and increased immune activation when HDAC inhibition is combined with proteasome blockade [48,83]. Here, HDAC9 is linked to squamous cell carcinoma.